Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT

Assertio Therapeutics Stock Analysis & Ratings

Assertio Therapeutics Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Assertio Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

ASRT

ASRT Stock Stats

Previous Close$2.2
Open$2.13
Bid2 x 620
Ask2.2 x 97
Today’s Range$2.01 - $2.215
52-Week Range$0.85 - $5.80
Volume1.09M
Average Volume1.15M
Market Cap$91.95M
Beta-1.18
P/E RatioN/A
EPS0.00
Earnings DateMar 10, 2022

Company Description

Assertio Therapeutics Inc

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
Sector
Healthcare
Industry
Drug Manufacturers
CEO
Daniel A. Peisert
Employees
27
Website
www.assertiotx.com
ISIN
US04546C2052
Address
100 South Saunders Road, Lake Forest, IL, 60045, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

ASRT FAQ

What was Assertio Therapeutics’s price range in the past 12 months?
Assertio Therapeutics lowest stock price was $0.85 and its highest was $5.80 in the past 12 months.
    What is Assertio Therapeutics’s market cap?
    Assertio Therapeutics’s market cap is $91.95M.
      What is Assertio Therapeutics’s price target?
      The average price target for Assertio Therapeutics is $4.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $4.00 ,the lowest forecast is $4.00. The average price target represents 94.17% Increase from the current price of $2.06.
        What do analysts say about Assertio Therapeutics?
        Assertio Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Assertio Therapeutics’s upcoming earnings report date?
          Assertio Therapeutics’s upcoming earnings report date is Mar 10, 2022 which is in 44 days.
            How were Assertio Therapeutics’s earnings last quarter?
            Assertio Therapeutics released its earnings results on Nov 04, 2021. The company reported $0.106 earnings per share for the quarter, beating the consensus estimate of N/A by $0.106.
              Is Assertio Therapeutics overvalued?
              According to Wall Street analysts Assertio Therapeutics’s price is currently Undervalued.
                Does Assertio Therapeutics pay dividends?
                Assertio Therapeutics does not currently pay dividends.
                What is Assertio Therapeutics’s EPS estimate?
                Assertio Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Assertio Therapeutics have?
                Assertio Therapeutics has 44,630,000 shares outstanding.
                  What happened to Assertio Therapeutics’s price movement after its last earnings report?
                  Assertio Therapeutics reported an EPS of $0.106 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 33.333%.
                    Which hedge fund is a major shareholder of Assertio Therapeutics?
                    Currently, no hedge funds are holding shares in ASRT

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis